BioInformant

Your Global Leader in Stem Cell Market Research

Home

The Cost Of Stem Cell Therapy in 2026-27

By 14 Comments

Add BioInformant as your Google Preferred Source
†Sponsored Content: The articel contains sponsored content. It is marked and identified where it appears.

How much is stem cell therapy today? According to analysis by BioInformant, the cost of stem cell therapy ranges from less than $5,000 for simple procedures to $25,000 or more for complex ones. In general, stem cell treatment procedures are paid out-of-pocket by patients, because they are not covered by medical insurance. The cost of platelet rich therapy (PRP), which can be used separately or in conjunction with stem cell therapy, is typically $500-700, but may be as high as $2,000 at some locations. [Read more…]

New Book “The Language of Healing” Tackles the Patient Education Gap in Regenerative Medicine

By 1 Comment

Add BioInformant as your Google Preferred Source
*Sponsored Content: The article is sponsored by Medical Longevity Institute. 

The regenerative medicine industry has a communication problem, and it isn’t a scientific one. The field now broadly accepts that mesenchymal stem/stromal cells (MSCs) exert their effects largely through paracrine signaling rather than engraftment and differentiation, a reframing captured in Arnold Caplan’s proposal to rename them “medicinal signaling cells.” What hasn’t matured is the public’s understanding of any of it. [Read more…]

REPROCELL Introduces StemEdit Platform
AI-Designed Genome Editors & Hypoimmune iPSC Lines

By Leave a Comment

Add BioInformant as your Google Preferred Source
*Sponsored Content: The article is sponsored by REPROCELL.

REPROCELL has launched StemEdit, a comprehensive gene editing platform for iPSCs and newly engineered iPSC lines enabled by OpenCRISPR-1™, an AI-designed genome editing system. The platform integrates high-fidelity genome engineering with predictive off-target modelling, designed to support research, translational development and future clinical applications. [Read more…]

Takara Bio Establishes Foothold in the Pluripotent Stem Cell Market

By 1 Comment

Add BioInformant as your Google Preferred Source
*Sponsored Content: The article is sponsored by Takara Bio.

A few years back, Takara Bio Takara Bio Europeannounced that the Medical Products Agency (“MPA”), the Swedish national authority responsible for regulation of drug and medical products, had granted the company a manufacturing license for derivation and banking of human embryonic stem (hES) cells to be produced under GMP conditions. The cells were to be produced at Takara Bio’s manufacturing laboratory located in Göteborg, Sweden, within Takara Bio Europe’s facility.

This announcement made Takara Bio the first company worldwide to offer this service for human ESCs.

Takara Bio’s Role with Human Pluripotent Stem Cells

The significance of this event is that Takara Bio is capable of providing a predictable and reliable source of hES cells for future cellular therapeutic development by sourcing starting material from FDA-compliant facilities, according to FDA guidelines and leveraging its proprietary, feeder-free hES cell establishment method, which is animal- and human-component free. [Read more…]

Shopping cart0
There are no products in the cart!
Continue shopping
0